CRXL buyout: It’s amusing that the author of this graphic from two years ago considered CRXL a target of buyout interest from NVS, GSK, SNY, and MRK—i.e. just about everyone except JNJ.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”